29 September 2021 - 11:50 am
In an article published here back in August 2021 titled “Barclays Global Healthcare Conference” we saw parts of a high-level discussion between two top Pfizer executives and a Senior Biopharma Analyst at Barclays Bank. The conversation revolved around being able to hike prices of “The Vaccine” at some point in the future, the “durability of the franchise” and also some other “blockbusters” that are on the horizon for Pfizer, Barclays Bank and other investors.
One of those blockbusters, cited in that meeting as a “another key growth driver” is a drug called Vyndaqel. As we saw in that article Vyndaqel was originally created to allegedly treat transthyretin amyloidosis (ATTR) which is a progressive disease that is said to lead to loss of nerve function (ATTR with polyneuropathy, ATTR-PN) or to heart disease (ATTR with cardiomyopathy, ATTR-CM).
Pfizer bought up the original company (FoldRx) that created this back in 2010. Here we are, 11 years later and this is suddenly a “key growth driver” worthy of mention alongside their mRNA COVID-19 injection which is likely to be the biggest win for them in some considerable time, if not all time. Why would that be?
The Pfizer execs talked about boosting the diagnosis rate to allow the sales of Vyndaqel to continue to grow, noting that numbers were already up by 170% so that in 2020 the revenue was £1.3 billion through getting the diagnosis rate up from 2% to 21% in the space of a year. They described how they’d done this with “broad awareness and education programs with our health care physicians, the appropriate use of noninvasive diagnostic procedures and then artificial intelligence and machine learning tools that we at Pfizer are developing to help support patient identification”.
They can do this because the rare hereditary form of ATTR is not the source of revenue. The source of revenue, growing revenue that is, is “wtATTR-CM” or “wild-type transthyretin amyloidosis with cardiomyopathy”. One of Pfizer’s “tools” that they mentioned above would be the website “Wild-Type EstimATTR-CM” made for Taiwanese health professionals.
As you can see, this is a Pfizer website, it’s description tag is “Use this AI based tool to learn about the combination of symptoms commonly associated with wtATTR-CM” and in the footer you can see it was “Developed and funded by Pfizer”.
Let’s set aside for a moment the world-championship levels of irony with Pfizer needing consent to store a web cookie on your browser as they simultaneously obfuscate almost every aspect of their COVID injections, removing all possibilities of informed medical consent, and ask why should we care about any of this?
The following three articles in varying levels of honesty (or not) demonstrate that myocarditis is a recognised “complication” of COVID-19 mRNA “vaccinations”…
- UK Government: https://www.gov.uk/government/publications/covid-19-vaccination-myocarditis-and-pericarditis-information-for-healthcare-professionals/information-for-healthcare-professionals-on-myocarditis-and-pericarditis-following-covid-19-vaccination
This problem affects young males disproportionately, and while it is claimed to be “rare”, given the virtual statistical risk to young people from the alleged “pandemic” virus is close to zero, playing this off as rare is just an attempt to sweep this under the rug. The UK Government states in their article that…
The existing evidence base shows that most patients with myocarditis post vaccination respond well to standard treatment, and the prognosis of the myocarditis is good. However, it may have long-term consequences and studies are in progress to further understand the longer-term consequences with follow up at 3 months and 6 months.https://www.gov.uk/government/publications/covid-19-vaccination-myocarditis-and-pericarditis-information-for-healthcare-professionals/information-for-healthcare-professionals-on-myocarditis-and-pericarditis-following-covid-19-vaccination
In some cases of non-COVID-19 vaccine-related myocarditis, the disease can progress to dilated cardiomyopathy and chronic heart failure, with evidence implicating myocarditis in 12% of sudden deaths in adults aged under 40. Likewise, the long-term prognosis of pericarditis is good, but it can become recurrent and rarely patients may develop constrictive pericarditis.
The claim that the “evidence base shows” anything, given there are no long-term safety studies is farcical, and they do acknowledge that the long-term consequences are unknown. The second paragraph talking about “non-COVID-19 vaccine related myocarditis” as if you can make the distinction that the “12% of sudden deaths in adults aged under 40” are a separate thing and this won’t apply here to this myocarditis is a typical baseless statement from the Government trying to play this down and disconnect otherwise young healthy people dropping dead, from the “vaccines”, as we have seen.
Now here we get back to Vyndaqel, as the Government line is that if you happen to get myocarditis, don’t worry there’s treatments for that too. In 2018 there was a study published titled “Myocarditis and cardiomyopathy” on the US NIH website. In that under the “recent findings” section it says:
Myocarditis has a variety of causes and a heterogeneous clinical presentation with potentially life-threatening complications. About one-third of patients will develop a dilated cardiomyopathy and the pathogenesis is a multiphase, mutlicompartment process that involves immune activation, including innate immune system triggered proinflammatory cytokines and autoantibodies.https://pubmed.ncbi.nlm.nih.gov/29528905/
We know the mRNA injections are causing changes to people’s immune systems, as that’s what they are intended to do. We also know that they are causing myocarditis. There are likely many more cases, less severe that don’t require hospitalisation as acknowledged by another study titled “Myocarditis following COVID-19 mRNA vaccination” cited by the UK Government’s JCVI. The “Myocarditis and cardiomyopathy” study demonstrates that cardiomyopathy is a direct consequence of myocarditis in a significant number of cases.
We can see from various sources that Vyndaqel is prescribed as a treatment for cardiomyopathy of wild-type transthyretin amyloidosis (wtATTR-CM) and we know Pfizer is banking (literally) on Vyndaqel revenues continuing to rise by getting diagnosis rates up.
Pfizer’s COVID-19 injection is directly contributing to the disease that they also sell a treatment (not a cure though it should be noted) for. They bought up FoldRx 11 years ago but while it was approved for the treatment of ATTR-PN (that’s ATTR with loss of nerve function) in the EU in 2011 and in Japan in 2013, it was rejected in the US.
But it was approved for a different form of ATTR that leads to heart disease, that being ATTR-CM (ATTR with cardiomyopathy) in the US in 2019, in the EU in 2020 and in Australia in March 2020.
While Pfizer was allegedly working on their COVID-19 mRNA injections that directly cause a rise in myocarditis that often leads to cardiomyopathy, they also got their treatment for cardiomyopathy “approved” in the places they are selling the most COVID jabs. Added to that, their top Investor Relations guys and Barclays Bank are discussing how much more money that Vyndaqel is going to make them.
If you are a coincidence theorist, you might like to pretend to yourself that these are all unrelated events, nothing to see here and there’s nothing nefarious going on. I would invite you to reconsider that position based on the overwhelming evidence presented above.